The previous findings show that the TNFR2 expression frequency on peripheral blood CD4 +  T cells can be an easily available and novel marker for predicting clinical outcomes or monitoring AML patients' progress [143]. The gene discussed is TNFRSF1B; the disease is acute myeloid leukemia.